Moody M Anthony, Gao Feng, Gurley Thaddeus C, Amos Joshua D, Kumar Amit, Hora Bhavna, Marshall Dawn J, Whitesides John F, Xia Shi-Mao, Parks Robert, Lloyd Krissey E, Hwang Kwan-Ki, Lu Xiaozhi, Bonsignori Mattia, Finzi Andrés, Vandergrift Nathan A, Alam S Munir, Ferrari Guido, Shen Xiaoying, Tomaras Georgia D, Kamanga Gift, Cohen Myron S, Sam Noel E, Kapiga Saidi, Gray Elin S, Tumba Nancy L, Morris Lynn, Zolla-Pazner Susan, Gorny Miroslaw K, Mascola John R, Hahn Beatrice H, Shaw George M, Sodroski Joseph G, Liao Hua-Xin, Montefiori David C, Hraber Peter T, Korber Bette T, Haynes Barton F
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Cell Host Microbe. 2015 Sep 9;18(3):354-62. doi: 10.1016/j.chom.2015.08.006.
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently targeted by neutralizing antibodies (nAbs) in infected individuals. In chronic infection, HIV-1 escape mutants repopulate the plasma, and V3 and CD4bs nAbs emerge that can neutralize heterologous tier 1 easy-to-neutralize but not tier 2 difficult-to-neutralize HIV-1 isolates. However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has not been studied. We describe the development and evolution in vivo of antibodies distinguished by their target specificity for V3 and CD4bs epitopes on autologous tier 2 viruses but not on heterologous tier 2 viruses. A surprisingly high fraction of autologous circulating viruses was sensitive to these antibodies. These findings demonstrate a role for V3 and CD4bs antibodies in constraining the native envelope trimer in vivo to a neutralization-resistant phenotype, explaining why HIV-1 transmission generally occurs by tier 2 neutralization-resistant viruses.
HIV-1包膜的第三个可变区(V3)环和CD4结合位点(CD4bs)经常受到感染个体中中和抗体(nAbs)的靶向作用。在慢性感染中,HIV-1逃逸突变体在血浆中重新出现,并且出现了能中和异源1级易中和但不能中和2级难中和HIV-1分离株的V3和CD4bs nAbs。然而,自体血浆病毒对这类nAb反应的中和敏感性尚未得到研究。我们描述了体内抗体的发育和演变,这些抗体的特点是对自体2级病毒上的V3和CD4bs表位具有靶向特异性,而对异源2级病毒则没有。令人惊讶的是,很大一部分自体循环病毒对这些抗体敏感。这些发现证明了V3和CD4bs抗体在体内将天然包膜三聚体限制为抗中和表型方面的作用,解释了为什么HIV-1传播通常通过2级抗中和病毒发生。